{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:00:56Z","timestamp":1791298856714,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jiac.2025.102852","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:33:35Z","timestamp":1762302815000},"page":"102852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period"],"prefix":"10.1016","volume":"31","author":[{"given":"Naoki","family":"Kawai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osame","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-4231","authenticated-orcid":false,"given":"Hideyuki","family":"Ikematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102852_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102852_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102852_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2025.102852_bib4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2208822","article-title":"VV116 versus Nirmatrelvir-Ritonavir for oral treatment of Covid-19","volume":"388","author":"Cao","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jiac.2025.102852_bib5","first-page":"1","article-title":"Real-world effectiveness of molnupiravir and nirmatrelvir\/ritonavir as treatments for COVID-19 in high-risk patients","volume":"228","author":"Paraskevis","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102852_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-Day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2025.102852_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102852_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 Study of ensitrelvir, a novel oral SARS-CoV-2 3C-Like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102852_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13338","article-title":"Efficacy and safety of ensitrelvir for asymptomatic or mild COVID-19: an exploratory analysis of a multicenter, randomized, phase 2b\/3 clinical trial","volume":"18","author":"Ohmagari","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.jiac.2025.102852_bib10","article-title":"Ensitrelvir for the treatment of nonhospitalized adults with COVID-19: results from the SCORPIO-HR, phase 3, randomized, double-blind, placebo-controlled trial","volume":"17","author":"Luetkemeyer","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102852_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/505868","article-title":"A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102852_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s10156-007-0538-3","article-title":"A change in the effectiveness of amantadine for the treatment of influenza over the 2003-2004, 2004-2005, and 2005-2006 influenza seasons in Japan","volume":"13","author":"Kawai","year":"2007","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102852_bib13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1086\/648424","article-title":"Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons","volume":"49","author":"Kawai","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102852_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10156-010-0179-9","article-title":"Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons","volume":"17","author":"Kawai","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102852_bib15","unstructured":"Goto T, Bando T, Mizoguchi M, Oribe Y, Tani N, Yong Chong, et al. Impact of the number of vaccinations on the duration of fever and symptoms in adult patients with mild COVID-19 during the period of spread of the omicron variant of SARS-CoV-2 in Japan. DOI:10.11150\/Kansenshogakuzasshi.e24011. (In Japanese. Abstract, figures, and tables are available in English.)."},{"key":"10.1016\/j.jiac.2025.102852_bib16","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40121-024-01010-4","article-title":"Real-world effectiveness of ensitrelvir in reducing severe outcomes in outpatients at high risk for COVID-19","volume":"13","author":"Takazono","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102852_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.12.003","article-title":"Ensitrelvir for the treatment of COVID-19: final analysis of a post-marketing surveillance from Japan","volume":"31","author":"Hayashi","year":"2025","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2025.102852_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102669","article-title":"The time to return-to-work in healthcare workers with COVID-19 treated with ensitrelvir, a novel oral inhibitor of 3C-like protease of SARS-CoV-2: an observational study utilizing pre-existing data from a single hospital","volume":"31","author":"Katsuta","year":"2025","journal-title":"J Infect Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:58:36Z","timestamp":1764323916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1341321X25002491"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102852","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durations of fever and other symptoms among COVID-19 outpatients administered ensitrelvir during the 2023 Japanese XBB epidemic period","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102852"}}